ARVN
Arvinas IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$489.07M
P/E Ratio
—
EPS
$-3.18
Beta
1.75
52W High
$14.51
52W Low
$6.05
50-Day MA
$9.60
200-Day MA
$10.67
Dividend Yield
—
Profit Margin
-247.50%
Forward P/E
17.86
PEG Ratio
—
About Arvinas Inc
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | $89.40M |
| Gross Profit (TTM) | $120.20M |
| EBITDA | $-246.50M |
| Operating Margin | -405.10% |
| Return on Equity | -42.30% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $1.30 |
| Book Value | $6.00 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | 5.47 |
| EV/Revenue | 0.0104 |
| EV/EBITDA | -1.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.70% |
| Shares Outstanding | $64.52M |
| Float | $55.95M |
| % Insiders | 7.76% |
| % Institutions | 83.28% |
Historical Volatility
HV 10-Day
63.89%
HV 20-Day
55.03%
HV 30-Day
54.20%
HV 60-Day
51.85%
HV Rank
54.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.80 target)
2
Strong Buy7
Buy8
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026